No compound on this page has been shown in a randomized human trial to make you less sore. The strongest human evidence here belongs to oral collagen peptides: in 55 men doing 12 weeks of training, collagen peptides brought maximal voluntary contraction (the most force a muscle can produce on demand) and jump height back faster after 150 drop jumps, while rated soreness did not budge (p = 0.66, which in plain terms means the difference was well inside the range you would get from chance alone) [[1]]. The injectables sold for this, meaning BPC-157, TB-500, GHK-Cu, CJC-1295, ipamorelin, IGF-1 LR3 and MOTS-c, have tissue-repair findings almost entirely from early research, none of them is an FDA-approved medicine, and none has been tested against recovery from a training session in people.
The best human recovery result in this entire category belongs to a powder you can buy in a supermarket, and even it did nothing for soreness. Twelve weeks of specific collagen peptides taken alongside training brought maximal voluntary contraction, rate of force development (how fast that force arrives) and countermovement jump height back significantly faster after 150 drop jumps, meaning the gap against placebo was larger than chance alone would produce, and left rated soreness untouched at p = 0.66 1. That split is how the rest of this page sorts the field: which of the three recovery outcomes a compound has been measured against, and in whom.
What does recovery mean, and what can a trial measure?
Recovery is sold on how you feel and measured as how much force you can produce. Those are different outcomes. A third sits underneath both, the proteins that spill out of damaged muscle fibers into the bloodstream, which a lab can count. A compound with evidence for one of the three has no evidence for the other two, and almost every claim in this category quietly swaps between them.
| The measurement | What it is, in plain words | How a trial captures it | What the collagen trial found |
|---|---|---|---|
| Soreness | The ache that builds 24 to 72 hours after unaccustomed work, especially lowering a weight under control. Researchers call it delayed onset muscle soreness, or DOMS. | The participant rates it on a scale, because there is no blood test for an ache | No difference against placebo, p = 0.66 1 |
| Force production | How hard you can push right now, how fast that force arrives, and how high you can jump from a standstill | Maximal voluntary contraction, rate of force development, countermovement jump height, measured before and repeatedly after a damaging session | All of them returned faster on collagen peptides than on placebo, by a margin larger than chance would produce, across 12 weeks of training 1 |
| Muscle damage markers in blood | Proteins that belong inside muscle fibers and end up in the bloodstream when fibers are torn up | Creatine kinase, lactate dehydrogenase and myoglobin, drawn over the days after the session | All three rose less on collagen peptides in the companion report from the same trial 2 |
There is a second split underneath the first one, and it decides which page you should be reading. Sore after a hard session is a training problem. A tendon that has been grumbling for eleven weeks is a structural problem, and almost the entire injectable evidence base in this category was built on the structural one, in early research, on tendon, ligament, gut lining and skin wounds. If the thing that brought you here has not settled in weeks, the injury recovery guide and the tendon page are the right context; if what you want is more muscle rather than faster turnaround, that is muscle growth, a different question with a different evidence base.
Repair runs in stages: inflammation, new blood vessels, cells arriving, collagen laid down, then remodelling. The stage you are stuck at is not the stage the next person is stuck at, which is most of why one compound feels like a miracle to one reader and like water to another. Best peptides for healing works through those stages in detail.
What peptides actually help with muscle recovery?
Here is the whole field on one screen, sorted by which recovery outcome was measured and in whom. The column that matters is the second one, because it is the column most rankings leave out.
| Compound | Which recovery outcome was measured | In whom | Strength of the evidence |
|---|---|---|---|
| Specific collagen peptides (oral) | Force production after a damaging session, and blood markers of muscle damage. Soreness was measured and did not change. | 55 men, 12 weeks of concurrent training, randomized and placebo-controlled 12 | The strongest here, and graded low certainty for functional recovery by its own meta-analysis of 19 studies in 768 people 3 |
| BPC-157 | Tendon, ligament, gut lining and wound repair. No post-training recovery outcome has been measured in people. | One uncontrolled report in patients with chronic knee pain; 35 of the 36 studies in the 2025 review were early research 4 | Weak in people. The review found no clinical safety data at all 4 |
| TB-500 | Movement of repair cells into damaged tissue, in early research. No recovery outcome in people. | No human trial in sports injury. The human trials in this space used the full 43-amino-acid protein, not the short fragment sold as TB-500 5 | Very weak. Indications, dosing, frequency and duration are all unknown 5 |
| CJC-1295 with ipamorelin | Growth hormone and IGF-1 concentrations in blood. Muscle force only in early research, in muscle loss caused by steroid medication. | Randomized trial in healthy adults, for hormones only, using the DAC version 6. The force finding is early research 5 | Real for hormone output, absent for recovery after training. The paired stack has the rest |
| GHK-Cu | Skin and wound outcomes, not muscle or tendon | No clinical data supporting it for musculoskeletal conditions 5 | None for muscle recovery. What GHK-Cu is good for has the dermatologic side |
| IGF-1 LR3 | Nothing recovery-related measured in people | No human trial for recovery from training | None |
| MOTS-c | Measured as a signal the body produces more of with training, not given as a treatment for recovery | No human trial of injected MOTS-c for recovery | None. MOTS-c explained covers what is known |
Studied for tissue repair, almost entirely before any human trial
Tendon, ligament, gut lining and skin wounds, in early research. None of the three has been tested against recovery from a training session in people.
Studied for hormone output, not for recovery outcomes
These raise growth hormone or IGF-1, which is measured in blood. The step from a hormone reading to a faster turnaround between sessions has not been made in any trial.
Studied as something training changes, not as a treatment
MOTS-c is a signal encoded in mitochondrial DNA whose levels shift with physical activity. No human trial has given it to anyone for recovery.
Compound by compound, and what each one has been measured against
Collagen peptides: the one compound here with a randomized trial against a recovery outcome
Specific collagen peptides are hydrolyzed collagen, which means collagen chopped into fragments short enough to survive digestion and show up in blood. The trial that anchors this page gave them daily for 12 weeks to 55 predominantly sedentary men aged 18 to 40 who were also doing concurrent training, and tested them with 150 drop jumps both before and after the 12 weeks, comparing how each group recovered. Maximal voluntary contraction, rate of force development, peak rate of force development and countermovement jump height all recovered significantly faster than on placebo. Rated soreness did not move, and body composition did not move 1. The companion report from the same participants found creatine kinase, lactate dehydrogenase and myoglobin, the proteins that leak out of damaged muscle, rose less in the collagen group 2. The published protocols used 15 g daily, and the 2023 paper discloses that a collagen manufacturer produced and supplied both the active powder and the placebo, which is a relevant fact when a page ranks a sponsor's product first.
For a tendon that has already gone wrong, the relevant trial is smaller and points the same way. Twenty patients with chronic mid-portion Achilles tendinopathy doing a structured calf-strengthening and return-to-running program were enrolled in a randomized crossover pilot, meaning each group took collagen for part of the study and placebo for the rest. In the first 3 months the group taking specific collagen peptides improved 12.6 points on the VISA-A questionnaire, which grades Achilles pain and function out of 100, against 5.3 points on placebo; after the groups swapped, the group moving onto collagen gained a further 17.7 points 7. It is a pilot in twenty people, the loading program did the structural work in both arms, and the authors conclude only that collagen may accelerate the benefit of that program. The 2024 meta-analysis of 19 studies in 768 adults rates this body of work moderate, low, low and very low across its four outcomes 3.
BPC-157: a large early-research base and one uncontrolled report in people
BPC-157 is a 15-amino-acid sequence originally identified in gastric juice, and it is the compound most people arrive here searching for. The 2025 systematic review in the HSS Journal is the most complete summary available: 544 papers screened across three decades, 36 included, 35 of them early research, one clinical study. That study is a retrospective report of BPC-157 injected into the knee joint for unspecified chronic knee pain, in which 7 of 12 patients described relief beyond 6 months, with no control group and no blinding 4. The same review notes that BPC-157 is broken down in the liver with a half-life under 30 minutes and cleared by the kidneys, and states in its own words that no clinical safety data were found 4.
That single report was about a knee rather than a training session, so the nearer context lives on joint pain and inflammation. How BPC-157 works covers the proposed mechanism, the study-by-study picture and sourcing cautions live in the monograph, and dose questions belong to the dosage guide, which owns them. The tendon and gut-lining work is interesting, and in thirty years it has not been carried into a controlled human trial. Nothing in that literature measured soreness, force production or damage markers after a training session.
The first video is a sports medicine physician going through the literature. The second is one person's account of using both BPC-157 and TB-500 and coming off them. It is a personal experience, not evidence, and it sits here as a counterweight to the enthusiastic version rather than as a data point.
TB-500 is two different molecules sold under one name
TB-500 is a short synthetic fragment modelled on thymosin beta-4, a 43-amino-acid protein the body makes. The two are sold under one name and they are not the same molecule: every human trial in this space, in severe dry eye, in venous leg ulcers and in intravenous safety testing, used the full protein, and none of them studied a sports injury. The 2026 review of injectable peptide therapy by orthopaedic surgeons at the Keck School of Medicine of USC covered TB-500 alongside BPC-157, CJC-1295 with ipamorelin, tesamorelin and GHK-Cu, and reported that indications, dosing, frequency and duration remain unknown for the group 5. Percentage figures for faster healing circulate widely for TB-500; they do not appear in the paper they are usually attributed to, and this page does not carry them. The TB-500 monograph holds the molecule distinction and the human trial list, and the dosage protocol page holds what published studies administered.
CJC-1295 with ipamorelin: real hormone data, no recovery data
CJC-1295 is a long-acting analog of growth hormone-releasing hormone, the brain signal that tells the pituitary gland to release growth hormone; ipamorelin works on a second receptor that does the same job through a different door. The human evidence is a set of randomized placebo-controlled ascending-dose trials in healthy adults, in which CJC-1295 with DAC raised growth hormone severalfold for six days or more and IGF-1 for 9 to 11 days after a single injection, with an estimated half-life of 5.8 to 8.1 days 6. That is the DAC version. What is sold and stacked with ipamorelin is usually the no-DAC form, which clears in minutes, so the one human dataset here was not generated on the product most readers would buy; the CJC-1295 page sets out the difference.
That trial measured hormone concentrations in blood. It did not measure a tendon, a muscle fiber or a recovery outcome. If you want to see those numbers on yourself rather than take a vendor's word for them, how to read peptide bloodwork and IGF-1 test timing cover what to draw and when. The nearest thing to a muscle result for the pair is early research, where the combination improved maximum tetanic tension, the peak force a muscle can generate when stimulated continuously, in muscle loss caused by steroid medication 5. The overnight-repair argument for this pair is an argument, not a finding.
Where the evidence for training recovery runs out
GHK-Cu is a copper-carrying tripeptide with a real dermatologic literature and, per the 2026 review, no clinical data supporting it for musculoskeletal conditions 5. Its evidence picture lives on the GHK-Cu page.
IGF-1 LR3 is a modified version of insulin-like growth factor 1, built to resist the binding proteins that normally hold the hormone in check. The claims made for it in training contexts have no human trial behind them, and it carries the low blood sugar risk described in the warning above.
MOTS-c is a short peptide encoded in mitochondrial DNA rather than in the chromosomes, and the published work concerns how much of it the body makes under different conditions, not what happens when it is injected for recovery. The MOTS-c explainer covers what is known.
The verdict on all three for training recovery is the same and it is short: nothing has been measured. They are on this page because they are marketed for it, not because anyone has looked.
While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown.Mayfield CK, Bolia IK, Feingold CL, et al., Keck School of Medicine of USC, American Journal of Sports Medicine, 2026 [[5]]
Are collagen peptides the same as BPC-157?
They share a word and nothing else. One is a food protein taken by mouth with randomized trial data against recovery outcomes; the other is a synthetic sequence taken by injection with a single uncontrolled report in people.
Collagen peptides against BPC-157, on matched rows
Can you stack BPC-157 and TB-500 for recovery?
People combine them because one is studied for the signalling that starts repair and the other for the cell movement that carries it out, and because the pair has a nickname that does most of the marketing. No trial has tested the combination in people for anything, so improving on both tells you the pair did something and not which half. Scheduling, half-lives and how the two overlap belong to the pairing guide, the named stack itself is reviewed on its own page, and if stacking is new to you, peptide stacking 101 covers why people combine things at all before you read a protocol.
What the studies ran, and what is known about harm
Published protocols are reported here as research, not as instructions. Dose questions belong to the guides that own them, and the most common way people get hurt in this category is misreading a research protocol as a prescription, which the dosing mistakes page covers.
| Compound | What published studies administered | Route used in those studies | How long before anything was measured | What is known about harm |
|---|---|---|---|---|
| Specific collagen peptides | 15 g daily of specific collagen peptides 13 | By mouth | 12 weeks of training before the drop-jump test, with recovery tracked over the following days 1 | No excess of adverse events was reported across the pooled trials 3. It is a food protein, which is not the same as risk-free for everyone: source matters for allergy and for dietary restriction (bovine, porcine, marine), and it has not been studied in pregnancy or in kidney disease. |
| BPC-157 | The single report in people used injection into the knee joint 4 | Into the joint in that report; early research used other routes | Patients in that report were followed past 6 months 4 | No clinical safety data were found by the 2025 review, and no carcinogenicity study exists 4 |
| TB-500 | No human protocol exists for sports injury 5 | Not established in people | Not established in people | Unknown. Indications, dosing, frequency and duration are all unknown 5 |
| CJC-1295 with ipamorelin | Single doses of CJC-1295 with DAC in the healthy-adult hormone trial 6 | By injection | Growth hormone and IGF-1 tracked for days after one dose 6 | No serious adverse reactions in the single-dose human trial; flushing, nausea and mild injection-site reactions appeared at the highest doses tested 6. No long-term human safety record, and raising IGF-1 for months has never been studied for safety in healthy people 5 |
Two practicalities that vendor pages skip, set down here as what handling involves rather than as instructions to self-administer anything. Peptide vials are shipped freeze-dried and are stable that way, but once mixed with bacteriostatic water they go in the refrigerator and have a working life measured in weeks, which is why the reconstitution guide and the injection hygiene guide exist. And price is the least useful thing to compare, because purity varies more than price does. Those pages describe handling; they are not an endorsement of injecting an unapproved compound, and that decision belongs with a clinician who knows your history.
If you already have a vial, three things still matter: what is actually in it, whether you are in a tested pool, which the legal status page settles, and whether it is being stored and handled cleanly. Grey-market, meaning sold outside any regulated supply chain and usually labelled for research use only, is the operative word for all of it. Independent testing of grey-market peptide samples has repeatedly found high failure rates on identity and purity, and measurable endotoxin, a bacterial contaminant that causes fever and inflammation, in a meaningful fraction of them. That is a larger and better-documented problem than anything about the molecule itself. This page prints no failure percentage, because the largest dataset circulating is an unreviewed preprint and the figures attached to it are routinely quoted as though it were a published paper.
Why does the same peptide protocol work for one person and not the next?
Before anyone reaches for genetics, five ordinary things explain most of the variance between two people running the same protocol, and they are ranked here by how much they usually account for.
- How unaccustomed the work was. Soreness is mostly a response to novelty, especially to lowering loads under control, and it shrinks on its own after two or three exposures to the same session. A compound started in week one of a new program gets credit for that.
- Sleep. It is the input most likely to be limiting in someone who trains hard and feels flat, and no vial substitutes for it.
- Protein and total energy intake. Under-eating while training hard produces exactly the flat, unrecovered feeling people buy peptides to fix.
- What is being measured. Someone tracking how sore they feel and someone tracking their bar speed will reach opposite conclusions about the same four weeks.
- What was in the vial. With grey-market failure rates as high as independent testing reports, a null result is at least as likely to be a sourcing story as a biology story.
Genetics sits below all five of those, and it is worth being exact about what it can and cannot tell you here. No trial of any compound on this page has sorted responders from non-responders by genotype, in people or in early research, including the widely repeated claim that a variant in the gene for the enzyme that makes nitric oxide in blood vessel walls (NOS3) marks who will respond to BPC-157. It is a mechanism hypothesis, nobody has tested it in a person, and this page does not carry it as anything more. What raw data can honestly do here is narrow which questions are worth asking rather than predict a response: the decision framework sets out where that line sits, and the 23andMe guide shows what is in the file you already have.
Why some people keep landing back in the same tendon
If you have re-injured the same Achilles or the same elbow three times while training partners on the same program have not, the more relevant literature is about connective tissue rather than muscle. COL5A1 is the gene for one of the proteins that sets how much stretch a tendon tolerates before it is damaged. A meta-analysis pooling 9 studies, 1,140 injury cases and 1,410 uninjured controls found the TT genotype at rs12722 associated with musculoskeletal soft tissue injury at an odds ratio of 1.58 (95% confidence interval 1.33 to 1.89), which is roughly a 58% higher chance of this kind of injury than in people carrying the other version: a nudge in the odds, not a diagnosis. The association held in Caucasian cohorts and did not reach significance in Asian ones, where the confidence interval ran from 0.46 to 4.60, and the pooled studies were small and individually conflicting 8.
Is BPC-157 legal in the US, and are these banned in sport?
BPC-157 and TB-500 came off the FDA's Category 2 list of bulk substances presenting significant safety risks in April 2026, after the nominations behind them were withdrawn. Neither was moved to Category 1, so neither is authorized for pharmacy compounding, and neither is an FDA-approved medicine. On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee voted to recommend BPC-157, TB-500 and KPV for the 503A bulks list, the list of raw substances a compounding pharmacy is allowed to work with, and recommended MOTS-c, epitalon and semax while voting down DSIP. The agency's own briefing documents ahead of that meeting proposed that these substances not be added. A committee recommendation is a recommendation. The rulemaking that would follow has not happened, so nothing is authorized today that was not authorized before the vote, and clinics that resumed compounding on the strength of the April action may be operating unlawfully. Ipamorelin and CJC-1295 took a worse path, with earlier committee votes going against both, and they remain restricted. The legal status page keeps the full timeline current, with the dates and the vote records.
There is no lawful route today for a consumer in the US to obtain BPC-157, TB-500, CJC-1295, ipamorelin, IGF-1 LR3 or MOTS-c for human use. None is an FDA-approved drug, none is authorized for pharmacy compounding, and material sold as a research chemical is by its own labelling not sold for human consumption. The FDA has also used import alerts against unapproved peptide drug products, so ordering from overseas is not a safe harbour. This page does not tell anyone where to buy any of them.
For anyone in tested sport the answer is simpler and harsher. BPC-157 is prohibited at all times as a non-approved substance. Thymosin beta-4 and its derivatives, which includes TB-500, growth hormone secretagogues including CJC-1295 and ipamorelin, and IGF-1 analogs including IGF-1 LR3 are all prohibited at all times as growth factors, and MOTS-c falls under the non-approved substances category as well. A prescription does not restore eligibility, and there is no permitted dose or washout, because these are banned outright rather than restricted in competition. Hydrolyzed collagen is not prohibited.
Link · Federal RegisterPharmacy Compounding Advisory Committee: notice of meeting and public docket, April 2026The FDA notice, published 16 April 2026, announcing the July advisory committee meeting and opening a public docket on the bulk drug substances nominated for the section 503A list.federalregister.gov Link · US Food and Drug AdministrationPharmacy Compounding Advisory Committee meeting, 23 to 24 July 2026The agency's own page for the meeting at which BPC-157, TB-500, KPV, MOTS-c, epitalon, semax and DSIP were voted on for the 503A bulks list, with the briefing materials attached.fda.gov Link · World Anti-Doping AgencyThe 2026 Prohibited ListThe current list itself, searchable, for anyone subject to testing who needs to check a substance rather than take a website's word for it.wada-ama.orgThe short version, for someone who trains hard and feels flat
- If the goal is to feel less sore, nothing on this page has been shown to do it, including the compound with the best trial, which measured soreness specifically and found no effect 1.
- If the goal is to produce force again sooner between sessions, collagen peptides are the one option here with randomized human data, and the certainty of that data is graded low by the people who pooled it 3.
- If the goal is a tendon that has not settled in weeks, a progressive loading program is doing the work, and collagen alongside it has a small positive pilot 7. The injectables in this category have early research and a regulatory status that is not approval.
- If a compound did nothing for you, sleep, food, novelty of the training and what was in the vial are more likely explanations than your genome. Neither the 36 studies in the 2025 BPC-157 review 4 nor the compounds surveyed in the 2026 orthopaedic primer 5 includes a trial that sorted responders by genotype.
Upload the raw DNA data you already have from 23andMe, AncestryDNA or MyHeritage and get all 39 peptides scored against the markers in your file, on association-level evidence rather than response prediction. A human reviews every report before it is sent, within 24 hours. The report is educational, it is not a medical or diagnostic test, and it does not tell you what to take.
Get your DNA report- Recovery is three measurements, and they do not move together
Soreness, force production and the muscle proteins that leak into blood are separate outcomes. In the best trial in this category, collagen peptides moved two of them and left soreness exactly where it was, so a compound with evidence for one of the three has no evidence for the other two. It is also why the injectable literature, built on structural repair in tendon, ligament and gut lining and almost entirely in early research, never touched the question this page asks: sorting the field by which outcome was measured, and in whom, produces a different order from sorting it by popularity.
Sources8
- Bischof K, Stafilidis S, Bundschuh L, Oesser S, Baca A, Konig D. Influence of specific collagen peptides and 12-week concurrent training on recovery-related biomechanical characteristics following exercise-induced muscle damage: a randomized controlled trial. Frontiers in Nutrition, 2023;10:1266056
- Bischof K, Stafilidis S, Bundschuh L, Oesser S, Baca A, Konig D. Reduction in systemic muscle stress markers after exercise-induced muscle damage following concurrent training and supplementation with specific collagen peptides: a randomized controlled trial. Frontiers in Nutrition, 2024;11:1384112
- Bischof K, Moitzi AM, Stafilidis S, Konig D. Impact of collagen peptide supplementation in combination with long-term physical training on strength, musculotendinous remodeling, functional recovery, and body composition in healthy adults: a systematic review with meta-analysis. Sports Medicine, 2024;54:2865-2888
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025;21(4):485-495
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 2026;54(1):223-229
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 2006;91(3):799-805
- Praet SFE, Purdam CR, Welvaert M, et al. Oral supplementation of specific collagen peptides combined with calf-strengthening exercises enhances function and reduces pain in Achilles tendinopathy patients. Nutrients, 2019;11(1):76
- Lv ZT, Gao ST, Cheng P, et al. Association between polymorphism rs12722 in COL5A1 and musculoskeletal soft tissue injuries: a systematic review and meta-analysis. Oncotarget, 2018;9(20):15365-15374
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
Frequently asked questions
Do peptides help with sore muscles?
No trial of the compounds on this page has shown a reduction in muscle soreness. The trial most often cited in support of the idea, 55 men taking specific collagen peptides across 12 weeks of training, measured soreness directly after 150 drop jumps and found no difference against placebo at p = 0.66, while force production did return faster [[1]]. Shorter supplement trials in this area report mixed results on soreness, which is part of why the best-controlled trial that measured it directly is the one worth reading. BPC-157, TB-500, GHK-Cu, CJC-1295 and ipamorelin have never been tested against soreness in people at all. If soreness is the thing you want gone, the evidence points at sleep, food and repeating the session that caused it rather than at anything in a vial.
How long does BPC-157 take to work?
There is no reliable answer, because the question has never been asked in a controlled human trial. The only report in people is a retrospective review of patients given BPC-157 into the knee joint for unspecified chronic knee pain, in which 7 of 12 described relief lasting beyond 6 months, with no control group and no blinding [[4]]. Timelines circulating online are extrapolated from early research in other tissues. The compound itself is broken down in the liver with a half-life under 30 minutes, so any claim about sustained tissue exposure has to explain that clearance first.
Are collagen peptides the same as BPC-157?
No. Collagen peptides are hydrolyzed collagen, a food protein chopped into fragments short enough to survive digestion, taken by mouth, sold as a dietary supplement, not prohibited in tested sport, and supported by a randomized placebo-controlled trial against force recovery [[1]] and by a twenty-person randomized crossover pilot in Achilles tendinopathy [[7]]. BPC-157 is a synthetic 15-amino-acid sequence taken by injection, not approved by the FDA for any indication, not authorized for compounding, prohibited in sport at all times, and supported in people by a single uncontrolled report [[4]]. They share the word peptide and nothing else that matters.
Are peptides for muscle recovery banned in sport?
BPC-157 is prohibited at all times for anyone subject to anti-doping testing as a non-approved substance. Thymosin beta-4 and its derivatives, which includes TB-500, growth hormone secretagogues such as CJC-1295 and ipamorelin, and IGF-1 analogs such as IGF-1 LR3 are prohibited at all times as growth factors. Prohibited at all times means in and out of competition, with no permitted dose and no washout period, and a prescription does not restore eligibility. Hydrolyzed collagen is a food protein and is not prohibited. Anyone in a tested pool should check the current Prohibited List directly rather than rely on any website, including this one.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.